Management of oral antiplatelet agents and anticoagulation therapy before bronchoscopy

Houssein A. Youness¹, Jean Keddissi¹, Ilya Berim², Ahmed Awab¹

¹Department of Medicine, Section of Pulmonary Diseases, Critical Care and Sleep Medicine, University of Oklahoma Health Sciences Center, OK, USA; ²Department of Medicine, Section of Pulmonary Diseases, Critical Care and Sleep Medicine, Creighton University, NE, USA

Contributions: (I) Conception and design: J Keddissi, A Awab, HA Youness; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Houssein A. Youness, MD. University of Oklahoma Health Sciences center, Pulmonary and Critical Care Section, Andrews Academic Tower, Suite 8400, 800 Stanton L Young BLVD, Oklahoma City, OK 73104, USA. Email: Houssein-Youness@ouhsc.edu.

Abstract: Although, bronchoscopy is a relatively safe procedure, small amount of bleeding in the airway can have serious consequences. Careful consideration of the risks of diagnostic and therapeutic bronchoscopic intervention can help minimize potential complications. With increasing number of patients using antiplatelet and anticoagulation therapies, strategies for minimizing thromboembolic and operative bleeding events need to be included in the risk and benefit analyses. Growing evidence suggests that aspirin is safe and does not increase bleeding during bronchoscopy. In addition, despite small studies reporting that it may be safe to perform bronchoscopic procedures that have low risk for bleeding such as endobronchial ultrasound with transbronchial needle aspiration on clopidogrel, it is still recommended to hold it for 7 days prior to performing elective bronchoscopy. It is recommended to hold vitamin K antagonist, as well as new oral anticoagulation agents prior to bronchoscopy. The timing for pre-procedural discontinuation of anticoagulation therapy and the decision to bridge depend on the agent used, the renal function and the thromboembolic risk. In this review article, we will discuss available data regarding management of anticoagulation and antiplatelet therapy as it applies to bronchoscopic procedures.

Keywords: Anticoagulation; antiplatelet therapy; newer oral anticoagulation agents (NOAC); bronchoscopy

Submitted Mar 20, 2017. Accepted for publication Apr 13, 2017.
doi: 10.21037/jtd.2017.05.45
View this article at: http://dx.doi.org/10.21037/jtd.2017.05.45

Introduction

Oral anticoagulants are used to prevent and treat thromboembolic disease in patients with mechanical cardiac valve, atrial fibrillation (AF), stroke, deep venous thrombosis, and pulmonary emboli. For years, vitamin K antagonists (VKA) have been the main antithrombotic agents. Newer oral anticoagulation agents (NOAC) such as dabigatran, rivaroxaban, apixaban and edoxaban have been introduced into clinical practice starting in 2010 and have been adopted rapidly by the physicians (1,2). For AF the use of the NOAC has matched the use of warfarin in 2014 (1). Oral antiplatelet therapy such as aspirin and clopidogrel is widely used to prevent arterial thrombosis such as heart attacks, strokes and in-stent thrombosis (3,4). It is estimated that over 30% of the adult population uses aspirin for primary or secondary prevention of cardiovascular disease (5). Thus, the practicing pulmonologist is likely to encounter a patient using at least one of these agents and requiring a bronchoscopy. Balancing the risk of bleeding during bronchoscopy to the risk of thrombosis while withholding these agents is the corner stone of the peri-procedural management of anticoagulation therapy. This article aims at summarizing the available evidence on management of platelet aggregation inhibitors, as well as anticoagulant prior to bronchoscopic interventions.
Assessment of bleeding risk during bronchoscopy

**General considerations**

The risk of bleeding depends on the type of bronchoscopic procedure performed (Table 1), the skill of the operator (22), as well as additional risk factors such as coagulopathy, uremia, liver disease, pulmonary hypertension and the anticoagulation/antiplatelet therapy used (23).

It is generally an accepted practice to correct thrombocytopenia of less than 50,000/µL, International normalized ration (INR) of more than 1.5 and partial thromboplastin time (PTT) of more than 50 seconds (11,24,25). However, robust data to back this approach is lacking. In fact, studies suggest no correlation between risk of bleeding with transbronchial biopsies and coagulopathy (26,27).

Uremia can cause platelet dysfunction. An increased risk of bleeding, up to 45% with transbronchial biopsies was reported in older studies (28,29). A later study demonstrated significantly lower bleeding rates (4%) in patients with renal dysfunction who received desmopressin (DDAVP) (30,31). Usually considered to be at least a relative contraindication, pulmonary hypertension may not increase the risk of bleeding with transbronchial biopsies either (32).

Compared to other endoscopic interventions, small volume of bleeding in the airway, which may not lead to hemodynamic instability, can still cause significant airway compromise. The severity of bleeding in bronchoscopic procedures is not standardized. Clinically significant bleeding was arbitrarily defined in prior studies as more than 20mL of blood present in lavage fluid (26), more than 50 mL (6), 100 mL (33), or the judgement of the bronchoscopist (34). Others, defined the grade of bleeding severity based on the intervention required to stop the bleeding: mild bleeding does not require endoscopic intervention, moderate bleeding stops within 3 min after endoscopic intervention (bronchial occlusion and/ or instillation of cold serum), and severe bleeding cannot be controlled endoscopically, causing hemodynamic or respiratory instability, and making it necessary to halt the procedure (17,35).

### Assessment of the risk of bleeding in various bronchoscopic procedures

**Broncho-alveolar lavage, bronchial brushing, transbronchial and endobronchial biopsy**

A review of Bronchoscopic procedures over a period of 9 years at the Cleveland clinic, showed significant bleeding in 0.83%, increasing to 1.9% with transbronchial biopsies (TBB) (11). In another large retrospective study of 4,273 bronchoscopies, which included 2,493 broncho-alveolar lavage (BAL) and 173 TBB, bleeding occurred in 0.12% of all bronchoscopies and in 2.8% of TBB (6).

In the original description of cytology brushing in 163 patients, only 14 patients (8.5%) had transient hemoptysis with no significant bleeding (35). Bronchial cytology brushing is usually used in conjunction with other diagnostic modalities, which have higher risk of bleeding, making it difficult to estimate its additional bleeding risk.

---

**Table 1** Bleeding rate in various bronchoscopic interventions; Low bleeding rate with airway inspection, BAL and EBUS; Intermediate bleeding rate with endobronchial forceps biopsy and TBB; High bleeding rate with endobronchial cryobiopsy, therapeutic bronchoscopy and transbronchial cryobiopsy

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Risk of bleeding</th>
<th>Overall bleeding rate (%)</th>
<th>Bleeding while on aspirin (%)</th>
<th>Bleeding while on clopidogrel (%)</th>
<th>Bleeding while on aspirin and clopidogrel (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Airway inspection/BAL</td>
<td>Low</td>
<td>&lt;0.12* (6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBUS</td>
<td>Low</td>
<td>0.2^ (7)</td>
<td>&lt;1 (8)</td>
<td>0–7.7 (8-10)</td>
<td>0–8.7 (8,9)</td>
</tr>
<tr>
<td>Endobronchial forceps biopsy</td>
<td>Intermediate</td>
<td>0.45 (11), 17.2^ (12)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TBB</td>
<td>Intermediate</td>
<td>1.9-5 (6,11,13-15)</td>
<td>3.5^ (13)</td>
<td>89 (14)</td>
<td>100 (14)</td>
</tr>
<tr>
<td>Endobronchial cryobiopsy</td>
<td>High</td>
<td>18.2^ (12)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic bronchoscopy, mean bleeding volume (mL) [min-max]</td>
<td>High</td>
<td>6.7 mL [0-30] (16)</td>
<td>6 mL [0-30]^ (16)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trans-bronchial cryobiopsy</td>
<td>High</td>
<td>9-53 (17-21)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*, Bleeding of more than 50 mL; ^, bleeding requiring intervention; "*, no statistically significant difference compared to not being on aspirin.
Endobronchial biopsy (EBB) adds to the bleeding risk of a diagnostic bronchoscopy with mild to moderate bleeding occurring in 0.45% (11). The risk is lower than the risk of TBB, presumably due to the ability to visualize and treat the lesion.

Endobronchial cryobiopsy was shown to improve the yield and decrease the number of biopsies needed for the diagnosis of endobronchial lesion. A randomized trial compared conventional forceps biopsy to flexible cryoprobe. 281 patients got endobronchial biopsies using forceps and 282 had biopsies performed using a flexible cryoprobe. There was no difference in the incidence of bleeding that required any intervention (17.2% vs. 18.2%) (12). The significantly higher rate of bleeding compared to other large series may be related to the higher incidence of endobronchial malignancy (95%).

**Transbronchial cryobiopsy**

Transbronchial cryobiopsy is rapidly gaining popularity as a diagnostic technique for the diagnosis of interstitial lung disease. The risk of bleeding seems somewhat higher than routine transbronchial biopsy. Estimates of bleeding come from small series of cases. In a series of 32 cases bleeding was moderate in 8/32 (25%) and was severe in 17/32 cases (53%) (18). A series of 33 patients reported mild or moderate bleeding in 9%, and 21% respectively (17). In a larger series of 74 patients, bleeding occurred in 16 patients (22%) (19). In a series of 25 patients, three patients (12%) experienced serious hemorrhage immediately after biopsy, including one patient who survived a life-threatening bleed (20). In a randomized controlled multicenter study, looking at the rate of bleeding with transbronchial cryobiopsy compared to forceps biopsy. The rate of clinically relevant bleeding was higher after the cryobiopsy procedures compared to the forceps biopsies (15.9% vs. 4.1%, P<0.05). No fatal bleeding complication occurred (21). Finally, a meta-analysis of 11 investigations for transbronchial cryobiopsy showed clinically relevant bleeding in 20.99% (36).

**Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA)**

EBUS-TBNA is generally considered low risk for airway bleeding (Table 1). One series reported 3,123 cases performed for staging and diagnosing lung cancer. EBUS-TBNA was performed 11,753 times (3.76/case). No cases of airway bleeding were reported (37). The ACQUIRE registry enrolled 1,317 patients at six hospitals. Airway bleeding requiring an intervention occurred in 0.2% only (7). A systematic review of 9,119 EBUS cases reported no airway bleeding complications (38). Another meta-analysis of EBUS-TBNA showed a complication rate of 0.15% in 1,299 cases (39).

**Interventional bronchoscopic procedures**

Interventional procedures are generally done with multimodality approach with a variety of therapeutic options available to control bleeding. These include electrocautery, laser, APC, balloon occluder as well as the large volume suction capacity and local compression capability of rigid bronchoscopy. As such the relatively low complication rate probably reflect the experience, skill of the operator and the setting in which it is done.

A large series of 775 rigid bronchoscopies performed at a university hospital found that the majority of patients had no complications. Most patients were being treated with multimodality approach for central airway obstruction. 51 patients (6.6%) hemorrhaged during the procedure. In 27 cases the bleeding was classified as moderate, in 4 cases, it was classified as severe (40).

In the ACCP AQuIRE registry data, 15 centers performed 1,115 therapeutic bronchoscopy procedures on 947 patients for the treatment of central airway obstruction. Six patients (0.5%) had bleeding requiring intervention (41). Overall we consider bronchoscopic procedures for airway inspection, BAL and EBUS to have a low risk of bleeding. Endobronchial biopsy and TBB have an intermediate risk of bleeding. Endobronchial cryobiopsy, therapeutic bronchoscopy and transbronchial cryobiopsy have a high risk of bleeding (Table 1).

**Management of anticoagulation in patients undergoing bronchoscopic procedure**

In addition to evaluating the bleeding risk related to the specific bronchoscopic procedure, patients receiving anticoagulation therapy should have an assessment of the risk of thromboembolism associated with withholding anticoagulation therapy.

In its risk classification system, the ACCP classified patients annual risk of thromboembolism as high if more than 10%, moderate if 5–10% and low if it is less than 5% (42) (Table 2). This recommendation was based on historical studies outside the perioperative setting for patients who
were not anticoagulated (42). However, in a study involving 1,185 patients, preoperative interruption of warfarin therapy (≤5 days), without bridging, was associated with low risk of thromboembolism (0.6%) in the following 30 days (43).

The British Thoracic Society guidelines recommend holding anticoagulation prior to bronchoscopy to minimize the perioperative risk of bleeding (23). The timing of interruption and the decision to bridge anticoagulation therapy depends on the risk of thromboembolic disease, the duration of action of the anticoagulant and the renal function (43,44) (Figure 1 and Table 3).

### Peri-procedural management of VKA in elective bronchoscopy

When no bridging is required, VKA should be stopped 5 days prior to the procedure to achieve an INR of less than 1.5 the day of the procedure (42). Since the decay of the anticoagulation effect of warfarin may be delayed in elderly (44), INR can be checked the morning of the procedure (48), or the day before, to allow for correction of elevated INR with low dose (1–2.5 mg) oral vitamin K (50).

When bridging is necessary due to high risk of for thromboembolic events, subcutaneous low molecular weight heparin (LMWH) or intravenous unfractionated heparin (UH) can be started when the INR falls below the therapeutic range. In high risk patients with an estimated creatinine clearance of less than 30 mL/min, the use of UH with close monitoring of the aPTT is the preferred option (48). It is recommended to stop LMWH for 24 hours prior to surgery and to hold UH for 4–6 hours prior to the surgery (42).

There are no specific data on when to resume anticoagulation after bronchoscopy. The recommendations are based on the perioperative management of anticoagulation before surgical procedures and gastrointestinal (GI) endoscopy. The 2013 ACCP guidelines recommend that post procedure, when hemostasis is achieved, warfarin can be resumed approximately 12 to 24 hours after the surgery (the evening of the procedure or next morning). If bridging is indicated heparin can be resumed 48–72 hours after the surgery, depending on the risk of bleeding post procedure (42). The British Thoracic Society guidelines recommend restarting warfarin the evening of the bronchoscopic procedure. Therapeutic dose LMWH should be omitted.

### Table 2 Assessment of the annual risk of thromboembolism without anticoagulation

<table>
<thead>
<tr>
<th>Indication for anticoagulation</th>
<th>High (&gt;10%)</th>
<th>Moderate (5-10%)</th>
<th>Low (&lt;5%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanical Heart Valve</td>
<td>Any mitral valve prosthesis</td>
<td>Bileaflet aortic valve prosthesis and one or more of the following risk factors:</td>
<td>Bileaflet aortic valve prosthesis without AF and no other risk factors</td>
</tr>
</tbody>
</table>

- AF
- Prior stroke or TIA
- HTN
- Diabetes
- CHF
- age >75 y

<table>
<thead>
<tr>
<th>AF</th>
<th>CHADS2 score of 5 or 6</th>
<th>CHADS2 score of 3 or 4</th>
<th>CHADS2 score of 0 to 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke or TIA within past 3 months</td>
<td>Stroke or TIA within past 6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatic valvular heart disease</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>VTE</th>
<th>VTE within the past 3-12 months</th>
<th>VTE &gt; 12 months previous and no other risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>VTE within past 3 months</td>
<td>VTE within past 3-12 months</td>
<td>VTE &gt; 12 months previous and no other risk factors</td>
</tr>
<tr>
<td>Severe thrombophilia (Protein C, S or antithrombin deficiency; antiphospholipid antibodies; factor V Leiden Homozygous)</td>
<td>Non-severe thrombophilia (heterozygous factor V Leiden or prothrombin gene mutation)</td>
<td>Recurrent VTE</td>
</tr>
<tr>
<td>Active cancer (treated within 6 months or palliative)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TIA, Transient ischemic attack; AF, AF; HTN, hypertension; CHF, congestive heart failure; VTE, venous thromboembolism; CHADS2 score = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke or transient ischemic attack; Adapted with permission from the American college of chest physician guidelines (antithrombotic therapy and prevention of thrombosis) (35).
**Figure 1** Management of oral anticoagulant therapy prior to bronchoscopy. INR, international normalized ratio; LMWH, low molecular weight heparin; UH, unfractionated heparin; NOAC, new oral anticoagulation agents. Modified based on the British thoracic society guidelines for diagnostic flexible bronchoscopy in adults (23), the American college of chest physician guidelines (antithrombotic therapy and prevention of thrombosis) (42) and the European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular AF (45).

**Table 3** Recommended timing for pre-procedure discontinuation of NOAC

<table>
<thead>
<tr>
<th>NOAC agent</th>
<th>Mechanism of action</th>
<th>Renal function (GFR in mL/min)</th>
<th>Recommended time to hold the medication (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Standard risk for bleeding</td>
<td>High risk for bleeding</td>
</tr>
<tr>
<td>Dabigatran (Pradaxa)</td>
<td>Direct thrombin inhibitor</td>
<td>&lt;30</td>
<td>2–4 (46); 4 (47)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>30–50</td>
<td>&gt;2 (46); 2 (47)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥50</td>
<td>1 (46,47)</td>
</tr>
<tr>
<td>Rivaroxaban (Xarelto)</td>
<td>Direct Factor Xa inhibitor</td>
<td>15 to &lt;30</td>
<td>4 (48)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>30–59</td>
<td>3 (48)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>60–90</td>
<td>2 (48)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;90</td>
<td>≥1 (48)</td>
</tr>
<tr>
<td>Apixaban (Eliquis)</td>
<td>Direct Factor Xa inhibitor</td>
<td>&lt;50</td>
<td>5 (48)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50–59</td>
<td>3 (48)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;60</td>
<td>1–2 (48)</td>
</tr>
<tr>
<td>Edoxaban (Savaysa)</td>
<td>Direct Factor Xa inhibitor</td>
<td>15 to &lt;50</td>
<td>2–3 (49)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50–80</td>
<td>1–2 (49)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;80</td>
<td>1 (49)</td>
</tr>
</tbody>
</table>

*Low risk procedures include BAL and EBUS-TBNA.
the day of the procedure and resumed the next day (23). Bridging therapy can be discontinued 5 days after starting warfarin and when the INR is in the therapeutic range (42).

The timing of resuming anticoagulation is based on the bleeding risk of the bronchoscopic intervention performed. High risk of bleeding has been defined as a risk of ≥1.5% for GI endoscopy (48). Given the much lower volume of bleeding required to cause significant airway compromise in the airway it is reasonable to adopt that as a minimum standard for bronchoscopy. We suggest that anticoagulation should be resumed later for procedure at higher risk from non-compressible biopsy sites such as TBB as compared to lower risk procedures such as BAL and EBUS-TBNA (Table 1).

**Evidence behind bridging therapy**

Only a few randomized controlled trial evaluated the use of bridging anticoagulation (51-53). In the BRIDGE study, a large randomized controlled trial in patients with atrial fibrillation (AF) undergoing an elective invasive procedure, forgoing bridging anticoagulation was not inferior to perioperative bridging with LMWH for the prevention of arterial thromboembolism. It resulted in fewer major bleeding episodes (1.3% vs. 3.2%; P=0.005) (53). Since only 3% of the patients had the highest CHADS2 scores of 5 and 6 and since these patients have an annual stroke risk of 12-18%, they would potentially still benefit from perioperative bridging anticoagulation (54). In a meta-analysis of 34 published studies, heparin bridging in patients receiving VKA was associated with higher rate of overall and major bleeding when compared to no bridging strategy. There was no difference in thromboembolic events (55). There are no studies assessing thromboembolic risk in high-risk patients with mechanical heart valve who had VKA interruption and did not receive heparin bridging (42).

The ACCP guidelines recommend bridging in patients with mechanical heart valve, AF or VTE when they are at high risk for thromboembolism. They recommend no bridging when these patients are at low risk for thromboembolism. When these patients are at moderate risk for thromboembolism an individualized approach is recommended (42).

**Peri-procedural management of new oral anticoagulant (NOAC) in elective bronchoscopy**

Currently there are four NOAC drugs approved by the Food and Drug Administration in the setting of AF and VTE. These include one oral direct thrombin inhibitor (Dabigatran) and three factor Xa inhibitors (Rivaroxaban, apixaban and edoxaban). They are given at a fixed dose and coagulation parameters do not need to be monitored (56).

Compared to warfarin, the NOAC have an immediate effect and shorter half-life (47). This allows them to be discontinued and resumed shortly prior and after the procedure. Bridging therapy is usually not thought to be necessary with these agents (56) and was not recommended by the European Heart Rhythm Association (45). The safety of performing invasive procedure in patients taking NOAC has been evaluated in the RE-LY (46), ROCKET AF (57) and the ARISTOTLE (58) trials.

In the RE-LY trial, Dabigatran had a similar periprocedural bleeding and thrombotic risk during elective, major and urgent procedures compared to warfarin. Early in the study, dabigatran was stopped 24 hours prior to the procedure; later on it was stopped from 2–5 days prior to high-risk procedure, depending on the patient's renal function (Table 3) (46).

Schulman et al conducted a prospective cohort study to evaluate the safety of a pre-specified protocol. The protocol was slightly modified from the RE-LY trial, bridging was not used, and dabigatran was started after hemostasis was achieved. For minor procedures, 75 mg was used the evening of the procedure and increased to 110 or 150 mg the morning of the procedure. For increased risk of bleeding, the resumption time was delayed for 48-72h after the surgery and starting with the regular dose. The rate of major bleeding in that study was 1.8%, minor bleeding occurred in 5.2% and thromboembolism occurred in 0.2% (47).

In the ROCKET AF trial, rivaroxaban and warfarin interruption pre-operatively was compared in patients with non-valvular AF. Study drug was stopped >3 days prior to the procedure in 90% of the cases, the median duration of interruption was 6 days in the rivaroxaban group compared to 5 days in the warfarin group. Bridging therapy was used at the discretion of the investigator and occurred in 9% of patient. LMWH was the main agent used for bridging. The risk of thromboembolism and stroke were not different among warfarin and rivaroxaban (0.42% vs. 0.27%). The rate of major and non-major bleeding were 1% and 3% respectively. There was no difference in the rate of major bleeding or thromboembolic complications in patients who received bridging and those who did not (57).

Investigators from the ARISTOTLE trial reported the outcomes of peri-procedural management of patients taking apixaban and warfarin. When apixaban was interrupted
Emergent bronchoscopy and anticoagulation reversal

In the instance of hemoptysis or foreign body extraction requiring bronchoscopic intervention in patients on anticoagulation, it may need to be reversed. Protamine can reverse heparin completely and LMWH partially. Vitamin K, prothrombin complex (PCC) and fresh frozen plasma can be used to antagonize VKA. Due to its small infusion volume and rapid availability, PCC is the agent of choice for emergent reversal of VKA.

Recombinant factor VIIa has been used to antagonize dabigatran, idarucizumab (Praxbind) has been approved for dabigatran reversal. In the presence of renal insufficiency, hemodialysis can be used to remove dabigatran (60,61).

No specific reversal agents are currently available for the remaining NOAC. Unlike dabigatran, rivaroxaban, apixaban and edoxaban are not dialyzable (56). Although of limited effect, PCC is recommended in life threatening circumstances when patients are using rivaroxaban or apixaban. Plasmapheresis can be considered as well in these patient (56). Andexanet alfa is currently being studied for apixaban, rivaroxaban and possible edoxaban reversal (62).

Management of antiplatelet therapy in patients undergoing bronchoscopic procedure

Platelet inhibitors are increasingly used for coronary artery, peripheral vascular and neurovascular diseases. They are classified based on their mechanism of action. Aspirin blocks the synthesis of prostaglandins and thromboxane A2 from arachidonic acid, therefore inhibiting platelets aggregation. Dipyridamole inhibits the breakdown of cyclic AMP and prevents platelet activation. The P2Y12 receptor blockers include ticlopidine, clopidogrel, ticagrelor, prasugrel, and cangrelor, block the binding of adenosine diphosphate to P2Y12, inhibiting platelet activation.

Since several of these agents (such as aspirin, clopidogrel, and ticlopidine) irreversibly inhibit platelet function, their short half-life is clinically irrelevant. Once these agents are stopped, 10% to 14% of normal platelet function is restored per day (42). For agents with reversible platelet function inhibition (such as dipyridamole and cilostazol), the effect depends on the elimination half-lives.

Assessment of the risk of withholding antiplatelet therapy

The risk of thrombotic events depends largely on the underlying indication for the antithrombotic therapy. Such indication should be the primary factor in determining if it is safe to withhold this therapy for procedures considered to be at risk for bleeding. As discussed above the risk of bleeding varies based on the type of bronchoscopic procedure performed (Table 1).

Patients taking antiplatelet therapy for primary prevention of myocardial infarction or stroke are considered to be at low risk for thrombotic events. On the other hand, patients with recent placement of a coronary stent (within...
3 to 6 months) or a recent myocardial infarction (within 3 months) are at high risk for a thrombotic event.

The American College of Chest Physicians recommends that patients receiving dual antiplatelet therapy for a coronary stent defer surgery for at least 6 weeks if a bare-metal stent is used and for at least 6 months if a drug-eluting stent is used (42). If surgery is needed within these time periods, the ACCP suggests continuing the dual antiplatelet therapy instead of stopping it 7 to 10 days before surgery. Even though the guidelines do not address patients undergoing bronchoscopies, one may extrapolate and conclude that stopping the dual antiplatelet therapy in such patients carries a high risk for a thrombotic coronary event.

**Peri-procedural management of antiplatelet therapy in elective bronchoscopy**

In a 2001 survey distributed at the American College of Chest Physicians meeting, aspirin was held by 71.5% of the respondents, while clopidogrel was held only by 61.3% prior to performing transbronchial lung biopsy via flexible bronchoscopy (63).

In 2002, Herth et al. evaluated the risk of bleeding associated with aspirin use during transbronchial lung biopsy in patients with no other coagulation problems (13). Bleeding severity was assessed based on the need for clinical intervention. Aspirin was not associated with an increased risk of bleeding, and the overall risk of severe bleeding was <1%. Subsequently, Ernst et al. prospectively evaluated the risk of bleeding associated with transbronchial biopsies in patients using clopidogrel with or without aspirin (14). Bleeding occurred in 89% and 100% of the patients, respectively. Even though no fatalities were observed in the study, all types of bleeding (minor/moderate/severe) were higher in the clopidogrel group.

EBUS-TBNA has been performed in patients who were on anti-platelet therapy. In a retrospective review of 409 EBUS-TBNA cases, 103 patients were on aspirin, 13 patients were on clopidogrel and 23 on both aspirin and clopidogrel. Overall bleeding events were low, occurring in 2.9% of all patients, 8.7% for patients on both aspirin and clopidogrel, 7.7% for clopidogrel alone, <1% for aspirin alone and 2.9% for patients not on any antiplatelet therapy. The difference was not statistically significant (P=0.164) (8). Another series reported twelve cases of EBUS-TBNA procedures performed on patients taking clopidogrel. Seven patients (66.7%) were taking aspirin in addition to clopidogrel. There was no significant bleeding seen in any cases at the time of bronchoscopy and no additional complications were identified during follow-up of at least 4 weeks (9). Martin et al. reported a series of fifteen patients on clopidogrel. A total of forty nodes were sampled. First, three passes per node were performed with a 22 gauge needle. If no complications were encountered, they followed with three passes with a 21-gauge needle. No significant bleeding occurred after the use of the 22 gauge or 21 gauge needles (10). Meena et al. reviewed 395 consecutive EBUS-TBNA. 37 patients were taking clopidogrel at time of biopsy. None were found to have significant bleeding (64).

The data regarding therapeutic bronchoscopies performed on antiplatelet agent is scarce. A large series report of multimodality therapeutic bronchoscopy done on anti-platelet therapy was reported by Harris et al. 108 patients had multimodality therapeutic bronchoscopy. 17 (15.7%) were taking aspirin and 91 (84.3%) were not on aspirin. The treatment modalities were similar in both groups except that more patients in the no aspirin group were treated with APC compared to the aspirin group (60.4% vs. 29.4%, P=0.031). The estimated blood loss between the aspirin and no aspirin groups was not significantly different. Overall, there was no difference in complications between both groups (16).

In the ACCP AQuIRE registry, 81 patients were reported to have high bleeding risk due to medications, but the agent used was not specified. There was no increase in the risk of complications or death in this group (41).

*Table 1* list the rate of bleeding as reported with various bronchoscopic procedures while on aspirin, clopidogrel or both.

The British Thoracic Society guideline recommends stopping clopidogrel 7 days prior to endobronchial or transbronchial biopsies (23). The same guidelines recommend continuing the use of aspirin (Figure 2).

In patients with a high risk of coronary stent thrombosis, intravenous bridging may be considered, using the reversible glycoprotein inhibitors epifibatide or tirofiban (65). Cangrelor, a reversible intravenous P2Y12-inhibitor may also be used (66). Low molecular weight heparin have no role in these patients and should not be used.

Finally, in urgent cases when one cannot wait for the effect of the anti-platelet agent to wear off, the need for the procedure should be carefully weighed against the risk of bleeding.

Precautions to reduce the risk of bleeding when bronchoscopy is performed include the following: First, the procedure should be performed by a pulmonologist
Figure 2 Management of oral antiplatelet therapy prior to bronchoscopy. Modified based on the British thoracic society guidelines for diagnostic flexible bronchoscopy in adults (7) and the American college of chest physician guidelines (antithrombotic therapy and prevention of thrombosis) (35).

Conclusions
Bronchoscopy is a relatively safe procedure with low overall risk of bleeding. However, even small volume of bleeding in the airway can be catastrophic. With the emergence of newer diagnostic and therapeutic options such as EBUS-TBNA, cryobiopsy, etc. the pulmonologist should be familiar with the bleeding risk associated with these procedures. Additionally, newer anticoagulant and antiplatelet agents are being used more frequently. The bronchoscopist should be familiar with strategies to minimize the risk of bleeding and thromboembolic events such as interruption of therapy, bridging and timely resumption of anticoagulation therapy post procedure. Since robust data is lacking, careful risk and benefit analyses individualized to each patient is prudent. A multidisciplinary discussion may help decision making in complex clinical scenarios.

Acknowledgements
None.

Footnote
Conflicts of Interest: The authors have no conflicts of interest to declare.
References


28. Zavala DC. Pulmonary hemorrhage in fiberoptic


